The antibody-drug conjugate (ADC) juggernaut powers on, with Japan’s Taiho Pharmaceutical Co. set to acquire Araris Biotech AG for up to $1.14 billion. Of that, $400 million will be up front, with the remainder tied to milestones with a maximum value of $740 million, around the progress of three ADCs for treating solid and hematological cancers.
Alteogen Inc. signed its first billion-dollar partnership this year for ALT-B4 technology through two separate contracts with Astrazeneca plc’s U.K.- and U.S.-based Medimmune subsidiaries worth up to $1.35 billion combined.
U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example of government waste as spending $8 million on “making mice transgender. This is real.” Skeptical media outlets jumped on the case right away.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Lundbeck, Otsuka, Springworks, Zai Lab.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Blue Earth, Cosciens, Ennodc, Grifols, Merck, Rivus, Shionogi, Transcode, UCB.
RSS
